S3V Vascular Technologies: India’s Bold Bet on High-End Stroke & Cardiac Devices

14 December 2025

Do you know India’s first indigenous thrombectomy device is being built by S3V Vascular?

It’s the same company that secured India’s first licence for an expandable titanium spinal cage, placing it at the frontier of neuro-spine innovation.

S3V Vascular Technologies, the Mysuru-based med-tech manufacturer, is emerging as one of India’s most ambitious players in neurovascular and cardiovascular devices. The company has spent the past decade building capabilities across stents, balloons, microcatheters, and guidewires.

• Backed by the Government of India’s Technology Development Board, S3V is developing India’s first fully indigenous mechanical thrombectomy device, a life-saving tool used to remove blood clots in stroke patients, a category long dominated by expensive imports.

• S3V Vascular Technologies had earlier attracted backing from veteran investor Madhusudan Kela, reinforcing confidence in India’s indigenous medtech innovation story.
  

S3V’s product family includes coronary devices (PTCA balloon catheters; 3V Paulo), stent systems (3V Siris/3V Neil), hydrophilic PTCA balloons, and newer neurovascular lines (Krome, clot-retriever concepts). The company is explicitly pursuing patents on key thrombectomy and catheter-construct innovations. That IP push is central to its strategy to move up the value chain, from contract manufacturing to proprietary, higher-margin devices.

S3V raised significant private capital (reported ~₹300 crore in a recent funding round) from high-profile investors and industrial backers, and has committed capex for an integrated manufacturing unit, previously reported as a ₹70–300 crore scale investment depending on the phase of facility buildout.